Revenue Analytics

Track your clinical trial revenue, payments, and financial performance.

Total Revenue

$109,350

+18.5% vs last year

All trials combined

This Month

$35,000

+12.8% vs last month

December 2024

Pending Payments

$8,850

2 payments due

Awaiting processing

Paid Amount

$100,500

95% collection rate

Successfully received

Monthly Revenue vs Target

Revenue by Trial Type

Cardiovascular$45,000

35% of total revenue

Diabetes$32,000

25% of total revenue

Hypertension$28,000

22% of total revenue

Oncology$23,000

18% of total revenue

Trial Revenue Breakdown

Trial	Sponsor	Patients	Visits	Total Revenue	Pending	Paid	Status
Cardiovascular Prevention Study CT-2024-001	Pfizer	15	45	$33,750	$5,250	$28,500	active
Diabetes Management Trial CT-2024-002	Takeda	8	24	$21,600	$3,600	$18,000	active
Hypertension Treatment Study CT-2024-003	Novartis	12	36	$24,000	$0	$24,000	active
Oncology Immunotherapy Study CT-2023-004	Bristol Myers Squibb	6	30	$30,000	$0	$30,000	completed

Recent Payment History

Cardiovascular Prevention Study

Visit Payment • Wire Transfer

2024-01-10

$8,750

paid

Diabetes Management Trial

Enrollment Bonus • ACH Transfer

2024-01-05

$6,000

paid

Hypertension Treatment Study

Milestone Payment • Wire Transfer

2023-12-28

$12,000

paid

Cardiovascular Prevention Study

Visit Payment • Wire Transfer

2024-01-15

$5,250

pending

Revenue Projections

Q1 2024 Projection$95,000

Annual Target$350,000

Based on current enrollment rates and trial timelines

Performance Metrics

$2,847

Avg. Revenue per Patient

$385

Avg. Revenue per Visit

95%

Collection Rate

Avg. Days to Payment